QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuronetics-inc-announces-new-publication-in-brain-stimulation-confirms-full-tms-treatment-course-is-vital

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 top-5-health-care-stocks-that-may-plunge-in-march

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 neuronetics-q4-gaap-eps-019-beats-026-estimate-sales-2031m-beat-1985m-estimate

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.26) b...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 earnings-outlook-for-neuronetics
Earnings Outlook For Neuronetics
03/04/2024 18:02:28

 neuronetics-reports-fy23-preliminary-unaudited-total-revenue-is-expected-to-be-over-71m-as-compared-to-previously-stated-guidance-of-70m-72m

Full Year 2023Preliminary unaudited total revenue is expected to be over $71 million as compared to previously stated guidance ...

 neuronetics-receives-fda-510k-clearance-for-neurosite-coil-placement-accessory-that-simplifies-measurement-and-coil-positioning-during-neurostar-transcranial-magnetic-stimulation-treatments

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 neurostar-elevates-depression-treatment-with-cutting-edge-technology-advancements

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 neuronetics-announces-continued-momentum-from-health-plans-for-tms-therapy-coverage

Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing ...

 neuronetics-q3-eps-033-misses-031-estimate-sales-1788m-beat-1758m-estimate

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.31)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION